argenx develops antibody-based medicines that target autoimmune diseases using its proprietary FcRn antagonist technology platform. Its lead product Vyvgart has been approved for the treatment of generalized myasthenia gravis and other autoimmune indications. The company focuses on patients with severe autoimmune conditions and continues to expand its pipeline of similar biologic therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 948 | — | 245.4 | 880.3% |
| Q3 2025 | 1,127 | — | 344.3 | 349.8% |
| Q4 2025 | 1,287.9 | — | 533 | 1,118.2% |
| Q1 2026 | 1,298 | — | 366 | 164.4% |
| Q2 2026 | 1,515 | 59.8% | 472 | 92.4% |
All markets — KeepWinning global stock screener
Other companies on Euronext Brussels: UCB SA (UCB), Elia Group SA/NV (ELI), Lotus Bakeries NV (LOTB), D'Ieteren Group SA (DIE), Ackermans & Van Haaren NV (ACKB), Sofina Société Anonyme (SOF)